Latest news with #KleinerPerkins
Bloomberg
5 hours ago
- Business
- Bloomberg
Figma and Backers Raise $1.2 Billion in IPO
Early Figma investor Mamoon Hamid, partner at Kleiner Perkins, says the depth of engagement with the software attracted him to the design platform back in 2018. As the company goes public, Hamid says they have room to grow with users. He speaks with Caroline Hyde at the New York Stock Exchange. (Source: Bloomberg)
Bloomberg
16 hours ago
- Business
- Bloomberg
How Podcast-Obsessed Tech Investors Made a New Media Industry
When Bucky Moore, a former partner at Kleiner Perkins, left his job for a gig at Lightspeed Venture Partners, he did a media tour. He broke the news on 20VC, then had a 45-minute conversation on the podcast Sourcery and wrapped up with the show TBPN, in an appearance that included an extended aside on a major issue with the weights in hotel gyms (not heavy enough). 'This is a big problem, and I'm glad you guys are talking about it,' Moore told TBPN 's hosts. Each podcast is hosted by a current or former venture capitalist. None is affiliated with anything resembling a traditional news publisher. Moore was tapping into a burgeoning media ecosystem serving the tech world, consisting of a startlingly wide array of podcasts, newsletters and streaming shows. There's even a print magazine or two. These days it may be easier to count the number of VC firms that have not started a media outlet than to tally the ones that have. Some of these offerings are boring and sycophantic; others are genuinely illuminating. Together, they're changing the way people learn about the technology industry.
Yahoo
a day ago
- Business
- Yahoo
Kleiner Perkins-backed Ambiq pops on IPO debut
Ambiq Micro, a 15-year-old manufacturer of energy-efficient chips for wearable and medical devices, closed its first day of trading on Wednesday at $38.53 a share, a 61% increase from the $24 IPO price the company set the previous day. The success of the IPO signals strong investor demand in the public market for new small-cap companies benefiting from AI innovation. Ambiq closed its first day as a public company with a valuation of $656 million (excluding employee options). This represents a significant increase from its last private funding valuation of $450 million in 2023, according to PitchBook. Ambiq has pitched itself as well-positioned to capitalize on the growth driven by AI. 'Because we're so low energy, we can put more intelligence and more AI on board' of edge processors, the company's CTO Scott Hanson told TechCrunch. For the three months that ended March 31, Ambiq posted a net loss of $8.3 million against revenues of $15.7 million, the company's S1 filing shows. The Q1 results mark a slight improvement from the first quarter of 2024, when the company reported a $9.8 million loss on $15.2 million in revenue. Kleiner Perkins and EDB Investments, a Singaporean state-backed entity, are the largest outside backers of Ambiq, according to the filing. Wen Hsieh, who was a general partner at Kleiner Perkins until 2023, first backed Ambiq when the company raised its Series C in 2014. Hsieh also invested in Ambiq after he launched his own venture firm, Matter Venture Partners, two years ago. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
TechCrunch
a day ago
- Business
- TechCrunch
Kleiner Perkins-backed Ambiq pops on IPO debut
Ambiq Micro, a 15-year-old manufacturer of energy-efficient chips for wearable and medical devices, closed its first day of trading on Wednesday at $38.53 a share, a 61% increase from the $24 IPO price the company set the previous day. The success of the IPO signals strong investor demand in the public market for new small-cap companies benefiting from AI innovation. Ambiq closed its first day as a public company with a valuation of $656 million (excluding employee options). This represents a significant increase from its last private funding valuation of $450 million in 2023, according to PitchBook. Ambiq has pitched itself as well-positioned to capitalize on the growth driven by AI. 'Because we're so low energy, we can put more intelligence and more AI on board' of edge processors, the company's CTO Scott Hanson told TechCrunch. For the three months that ended March 31, Ambiq posted a net loss of $8.3 million against revenues of $15.7 million, the company's S1 filing shows. The Q1 results mark a slight improvement from the first quarter of 2024, when the company reported a $9.8 million loss on $15.2 million in revenue. Kleiner Perkins and EDB Investments, a Singaporean state-backed entity, are the largest outside backers of Ambiq, according to the filing. Wen Hsieh, who was a general partner at Kleiner Perkins until 2023, first backed Ambiq when the company raised its Series C in 2014. Hsieh also invested in Ambiq after he launched his own venture firm, Matter Venture Partners, two years ago.
Forbes
4 days ago
- Health
- Forbes
OpenEvidence's Meteoric Rise Is Huge For Doctors
Medical research and science has never been easier to access. OpenEvidence has raised hundreds of millions of dollars. In its most recent funding round, it raised a $210 million Series B from prominent investors such as Google Ventures and Kleiner Perkins, bringing the company's valuation to nearly $3.5 billion. The company's goal is straightforward and incredibly ambitious: to collate the entire corpus of medical knowledge and research developments in a way that is easily accessible to physicians and thereby, improve health outcomes. The service is aiming to provide a similar 'touch and feel' as other generative AI services such as Chat GPT or Google's Gemini—except, its target audience is primarily doctors. Medical science is a rapidly evolving field with a perpetually expanding sea of knowledge, especially as research and development across the fields of disease, therapeutics and human sciences continue to grow. In fact, as Sequoia Capital notes, 'a new PubMed article [which is often the flagship resource for peer-reviewed science studies]The value of this type of technology is increasingly being recognized. The latest models for OpenAI's ChatGPT (GPT 4.1 and o3) have displayed incredible efficacy in taking command of medical knowledge; in May, the company published its work with HealthBench, proposing a rubric for model performance in healthcare and also indicating that GPT's latest models performed at par or even better than standard physician evaluations. Even Google's Gemini family of models has made significant progress in this space; its MedLM suite, for example, is a highly tuned model that can aid the entire healthcare workflow, ranging from answering medical questions to deciphering unstructured health data. Why is all of this important? There are a few different reasons. First and foremost, this technology is aiming to democratize medical knowledge in a way that is easy to access. Furthermore, it comes at a time when the healthcare system, and its respective workforce, is facing unprecedented headwinds. Studies have repeatedly indicated that physician burnout and attrition are incredibly concerning problems for health systems and organizations of all sizes; physicians simply do not have the bandwidth to fulfill all of their patient care duties in addition to the increasingly prevalent administrative, compliance and regulatory burdens placed on them. This also means that there is less time for professional development and continuing education. These technologies can serve as a major advantage to the physician workflow as they provide an opportunity to easily query, fact-check and understand the latest science that is involved with a condition. Carry this even further with tools such as OpenEvidence DeepConsult, which gives physicians access to PhD-level AI agents that can conduct medical research, or Gemini's foundation models that can rapidly decipher medical images, or even AI scribing technology that can rapidly generate patient-physician encounter notes, and soon, hours can be saved from a physician's daily workflow. This translates not only to millions of dollars saved annually in system costs, but also to more time available to spend with patients, improved access to care, and ultimately, increased efficacy and quality of care provided.
